GlobeNewswire PharmaceuticalsQwen · 实盘不做把握 9/10不做原因:不是事件
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:01:17·⚡ 决策 09-01 19:12:03 +10m46s·56.1 天前
Syndax Pharmaceuticals宣布管理层将参加9月两场投资者会议
这是标准的投资者会议参与公告，仅通知管理层将出席两场会议炉边谈话，不含任何新临床数据、监管决定、财务指引变化、订单、合作或任何可能改变公司价值的新增事实。属于纯例行IR沟通，无交易方向、无催化、无edge。
📄 原文GlobeNewswire Pharmaceuticals↗ 原文
Syndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutica…
不做 Syndax Pharmaceuticals（SNDX.US）
纯例行投资者会议参与公告，无任何新增实质信息（无临床数据、无监管进展、无财务指引、无合作/订单），不构成可交易催化，无方向、无edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Syndax发布的是标准投资者会议日程公告，CEO将参加9月10日Citi会议和9月15日H.C. Wainwright会议的炉边谈话。公告不含任何新临床结果、监管进展、商业化里程碑、财务指引或合作信息。会议本身在1-2周后，即使届时可能有新信息，当前公告也不构成可交易事件。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
原文全文
展开原文 · 1,552 字
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Citi 2026 Biopharma Back to School Conference
in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
H.C. Wainwright 28th Annual Global Investment Conference
in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at
www.syndax.com
, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj
®
(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit
www.syndax.com
or follow the Company on
X
and
LinkedIn
.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
Citi 2026 Biopharma Back to School Conference
in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
H.C. Wainwright 28th Annual Global Investment Conference
in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at
www.syndax.com
, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj
®
(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit
www.syndax.com
or follow the Company on
X
and
.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。